Advertisement

Application of Immunohistochemistry in Basic and Clinical Studies

  • Aihua LiEmail author
  • Dong-Hua YangEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2108)

Abstract

Immunohistochemistry (IHC), also known as immunohistochemical staining, is an immune morphological analysis. It is a process of selectively identifying antigens (proteins) by antibodies in cells or tissue sections. This chapter introduces the procedure and application of immunohistochemistry. Although immunohistochemistry has a vast application in basic and clinical studies, this chapter focuses on its application in biomarker study, particularly in biomarkers that related to cancer diagnosis, prognosis, and drug development. Detail protocol of immunohistochemistry in formalin-fixed and paraffin-embedded tissue sections is included.

Key words

Immunohistochemistry Immunofluorescence Biomarkers Diagnostics Cancer treatment 

References

  1. 1.
    Coons AH, Creech HJ, Jones RN (1941) Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med 47:200–202CrossRefGoogle Scholar
  2. 2.
    Childs GV (2014) History of immunohistochemistry. In: McManus LM, Mitchell RN (eds) Pathobiology of human disease. Elsevier, San Diego, pp 3775–3796CrossRefGoogle Scholar
  3. 3.
    Lindenmann J (1984) Origin of the terms “antibody” and “antigen”. Scand J Immunol 19(4):281–285CrossRefGoogle Scholar
  4. 4.
    The Nobel Prize in Physiology or Medicine (1901) nobelprize.org. https://www.nobelprize.org/prizes/medicine/1901/summary/
  5. 5.
    The Nobel Prize in Physiology or Medicine (1908) nobelprize.org. https://www.nobelprize.org/prizes/medicine/1908/summary/
  6. 6.
    Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95CrossRefGoogle Scholar
  7. 7.
    Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative (2010) AACR-FDA-NCI. Cancer biomarkers collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16:3299–3318CrossRefGoogle Scholar
  8. 8.
    Smith NR, Womack C (2014) A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery. J Pathol 232(2):190–198CrossRefGoogle Scholar
  9. 9.
    Howat WJ, Lewis A, Jones P et al (2014) Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods 70(1):34–38CrossRefGoogle Scholar
  10. 10.
    Shi SR, Liu C, Taylor CR (2007) Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem 55(2):105–109CrossRefGoogle Scholar
  11. 11.
    Zu W, Li A, Chen T (2015) Rabbit monoclonal antibody. In: Fan L, Jeffrey P (eds) Handbook of practical immunohistochemistry: frequently asked questions, 2nd edn. Springer, New YorkGoogle Scholar
  12. 12.
    Schacht V, Kern JS (2015) Basics of immunohistochemistry. J Invest Dermatol 135:e30CrossRefGoogle Scholar
  13. 13.
    Werner M, Chott A, Fabiano A et al (2000) Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24(7):1016–1019CrossRefGoogle Scholar
  14. 14.
    Grizzle WE (2009) Models of fixation and tissue processing. Biotech Histochem 84(5):185–193CrossRefGoogle Scholar
  15. 15.
    Taylor CR, Shi SR et al (1996) Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech Histochem 71(5):263–270CrossRefGoogle Scholar
  16. 16.
    Lott R, Tunnicliffe J, Sheppard E et al (2015) Practical guide to specimen handling in surgical pathology. College of American Pathologist, Northfield, ILGoogle Scholar
  17. 17.
    Yang DH, Smith ER, Roland IH, Sheng Z, He J, Martin WD, Hamilton TC, Lambeth JD, Xu XX (2002) Disabled-2 is essential for endodermal cell positioning and structural formation during mouse embryogenesis. Dev Biol 251:27–44CrossRefGoogle Scholar
  18. 18.
    Yang DH, Kasamo H, Miyauchi M, Tsuyama S, Murata F (1996) Ontogeny of sulfated glycoconjugate producing cells in the rat fundic gland. Histochem J 28:33–43CrossRefGoogle Scholar
  19. 19.
    Yang DH, Tsuyama S, Ge Y-B, Ohmori J, Wakamatsu D, Murata F (1997) Proliferation and migration kinetics of stem cells in the rat fundic gland. Histol Histopathol 12:717–728Google Scholar
  20. 20.
    Yang DH, Tsuyama S, Ohmori J, Hotta K, Katsuyama T, Murata F (1999) Phenotypic immunostaining of mucus-secreting cells of foregut origin. Acta Histochem Cytochem 32(2):135–140CrossRefGoogle Scholar
  21. 21.
    Yang DH, Tsuyama S, Murata F (2001) The expression of gastric H-K-ATPase mRNA and protein in developing rat fundic gland. Histochem J 33:159–166CrossRefGoogle Scholar
  22. 22.
    Yang DH, Tsuyama S, Hotta K, Katsuyama T, Murata F (2000) Expression of N-acetylglucosamine residues in developing rat fundic gland cells. Histochem J 32(3):187–193CrossRefGoogle Scholar
  23. 23.
    Yang DH, Moss EG (2003) Temporally regulated expression of Lin-28 in diverse tissue of the developing mouse. Gene Expr Patterns 3(6):719–726CrossRefGoogle Scholar
  24. 24.
    Yang DH, Smith ER, Cohen C, Patriotis C, Godwin AK, Hamilton TC, Xu XX (2002) Molecular events associated with dysplastic morphological transformation and initiation of ovarian tumorigenicity. Cancer 94:2380–2392CrossRefGoogle Scholar
  25. 25.
    Yang DH, Fazili Z, Smith ER, Cai Q, Klein-Szanto A, Cohen C, Horowitz IR, Xu XX (2006) Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53 null background. Am J Pathol 169:258–267CrossRefGoogle Scholar
  26. 26.
    Yang DH, Cai KQ, Roland IH, Smith ER, Xu XX (2007) Disabled-2 is an epithelial surface positioning gene. J Biol Chem 282(17):13114–13122CrossRefGoogle Scholar
  27. 27.
    Yang DH, Smith ER, Cai KQ, Xu XX (2009) c-fos elimination compensates for disabled-2 requirement in mouse extraembryonic endoderm development. Dev Dyn 238(3):514–523CrossRefGoogle Scholar
  28. 28.
    Yang DH, McKee KK, Chen ZL, Mernaugh G, Strickland S, Zent R, Yurchenco PD (2011) Renal collecting system growth and function depend upon embryonic gamma1 laminin expression. Development 138(20):4535–4544CrossRefGoogle Scholar
  29. 29.
    Khan SA, Yang DH, Zhu F, Dubyk C, Tejani M, Cohen SJ, Hoffman JP, Burtness BA (2012) Survivin expression with resected pancreatic adenocarcinoma. Cancer Res 72(8):714–714Google Scholar
  30. 30.
    Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang DH, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA (2013) p16 status, pathologic and clinical characteristics, biomolecular signature, and long term outcomes in unknown primary carcinomas of the head and neck. Head Neck 36(12):1677–1684CrossRefGoogle Scholar
  31. 31.
    Mekee KK, Yang DH, Patel R, Chen ZL, Strickland S, Takagi J, Sekiguchi K, Yurchenco PD (2012) Schwann cell myelination requires integration of laminin activities. J Cell Sci 125(Pt 19):4609–4619.  https://doi.org/10.1242/jcs.107995. #equal contribution 1st authorCrossRefGoogle Scholar
  32. 32.
    Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov IA (2013) Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation. Cancer Discov 3(1):96–111.  https://doi.org/10.1158/2159-8290.CD-12-0031.CrossRefPubMedGoogle Scholar
  33. 33.
    Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai K, Klein-Szanto AS, Cunningham D, Kratz L, Herman G, Golemis EA, Astsaturov I (2015) Endogenous sterol metabolites regulate growth of EGFR/KRAS-dependent tumors via LXR. Cell Rep 12(11):1927–1938.  https://doi.org/10.1016/j.celrep.2015.08.023CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kudinov A, Deneka A, Nikonova A, Beck T, Ahn Y, Liu X, Yang DH, Golemis E, Boumber Y (2016) Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A 113(25):6955–6960.  https://doi.org/10.1073/pnas.1513616113CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS (2014) Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol 89(1):52–61CrossRefGoogle Scholar
  36. 36.
    Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova A, Golemis EA, Flieder DB, Cooper H, Lango MN, Ridge JA, Burtness B (2013) Quantification of excision repair cross complementing group 1 (ERCC1) and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res 19(23):6633–6643CrossRefGoogle Scholar
  37. 37.
    Egloff AM, Lee JW, Langer C, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang DH, Mehra R, Ridge JA, Patel UA, Burtness B, Forastiere AA (2014) Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group trial E3303. Clin Cancer Res 20(19):5041–5051CrossRefGoogle Scholar
  38. 38.
    Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, Mehra R, Sharma R, Gaffney SG, Perry EB, Townsend JP, Serebriiskii IG, Golemis EA, Issaeva N, Yarbrough WG, Koo JS, Burtness BA (2019) Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck. Clin Cancer Res 25(11):3430–3442CrossRefGoogle Scholar
  39. 39.
    Xu S, Yao H, Luo S, Zhang YK, Yang DH, Li D, Wang G, Hu M, Yao H∗, Wu X, Chen ZS, Xu J. (2017) A potent anticancer optimized from natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway, J Med Chem, 60(4):1449-1468. doi:  https://doi.org/10.1021/acs.jmedchem.6b01652CrossRefPubMedGoogle Scholar
  40. 40.
    Pileri SA, Roncador G et al (1997) Antigen retrieval techniques in immunohistochemistry: a comparison of different methods. J Pathol 183(1):116–123CrossRefGoogle Scholar
  41. 41.
    O’Leary TJ (2001) Standardization in immunohistochemistry. Appl Immunohistochem Mol Morphol 9(1):3–8PubMedGoogle Scholar
  42. 42.
    Lin F, Chen Z (2014) Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Arch Pathol Lab Med 138(12):1564–1577CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Epitomics—An Abcam CompanyBurlingameUSA
  2. 2.Department of Pharmacology, College of Pharmacy and Health SciencesSt. John’s UniversityQueensUSA

Personalised recommendations